When to use this playbook
- Your company is eight weeks from HIMSS, HLTH or ViVE and needs to turn a business milestone into credible news.
- An expected FDA clearance could coincide with a conference, but the permissible product claims still need regulatory and legal review.
- A health system partnership announcement requires both organizations to approve the language, quotes, timing, logos and supporting assets.
- A funding round, product launch or clinical milestone needs to earn attention during a crowded conference news cycle.
- Your internal marketing team needs one agency to coordinate media relations, executive preparation, conference content, design and post-event promotion.
What success looks like
A successful announcement is an approved, coordinated launch rather than a press release sent during a conference. The narrative, claims, spokesperson language, media outreach, website, social posts, booth materials, session content and follow-up program all tell the same story.
Coverage cannot be guaranteed. The controllable outcome is a launch that gives relevant journalists enough time and evidence to evaluate the news, prepares executives for difficult questions and creates useful content after the event ends.
Choose the critical path before choosing the headline
| Announcement type | Controlling constraint | What makes it newsworthy | What the agency must run |
|---|---|---|---|
| Conference announcement | A compressed news cycle with many companies competing for attention in the same 48 hours | A material development that matters outside the conference, with the event providing relevance and access | Embargo management, briefing scheduling, spokesperson preparation, day-of outreach and synchronized event assets |
| FDA clearance announcement | The exact clearance, intended use, indications, supporting evidence and approved claim language | What the clearance enables for the intended user, patient population or clinical workflow | A controlled claims matrix, regulatory review, evidence-led messaging and precise pathway terminology |
| Health system partnership | A second organization’s communications, legal and executive approval process | What is being implemented, for whom, at what scale and why the health system selected the approach | A joint approval calendar, partner quotes, logo clearance, coordinated outreach and shared spokesperson preparation |
The eight-week announcement countdown
| Timing | Primary decision | Required outputs |
|---|---|---|
| Week 8 | Confirm the news type, target date, approval owners and conference role | Launch charter, approval map, known facts and risk list |
| Week 7 | Establish the factual and regulatory source of truth | Claims matrix, evidence file, partnership facts or financing details |
| Week 6 | Lock the central narrative and proof hierarchy | Headline direction, message house, proof points and media Q&A |
| Week 5 | Build every asset needed on announcement day | Release, media brief, web copy, visuals, social content, booth and session materials |
| Weeks 4 to 3 | Start selective embargoed outreach and conference briefing scheduling | Priority media pitches, briefing calendar and day-of target list |
| Weeks 2 to 1 | Complete approvals and prepare spokespeople | Final assets, mock interviews, approved responses and event logistics |
| Announcement day | Publish and coordinate every channel | Targeted outreach, interviews, website, social, email, booth and sales activation |
| Weeks 1 to 6 after | Turn the milestone into an ongoing authority program | Executive content, customer proof, search content, sales follow-up and new media angles |
Worked basis: SVM prepared Pear Suite’s Series A narrative around its AI-powered platform, provider-network growth and expansion through Medicaid and Medicare health plan contracts. SVM began embargoed outreach before HLTH and followed with day-of outreach to healthcare trade, national health and local media. The timeline above converts that published sequence into a reusable operating plan. SVM Pear Suite funding campaign
Step 1: Establish the launch authority at week eight
Action: Create a one-page charter naming the announcement, target date, business objective, audiences, spokespersons and final decision-makers. Assign one owner for the master copy and one final approver for each organization or specialist function.
- For conference news, confirm whether the event is central to the story or simply the launch venue.
- For FDA clearance, give regulatory and legal reviewers explicit ownership of the permissible claim set.
- For a health system partnership, obtain the partner’s communications contact, approval stages and required lead time immediately.
Expected outcome: Every participant knows who can change the language, who can approve it and when the final materials must be ready.
Gotchas: Do not treat conference attendance as the news. Avoid combining a product launch, partnership and regulatory milestone unless each element is final and the combined story is clearer than separate announcements.
Estimated working time: 90 minutes for the kickoff, followed by one business day to document owners and deadlines.
Step 2: Build a controlled source of truth at week seven
Action: Assemble the documents that determine what the company can state publicly. Turn them into a claims and approvals matrix used across the press release, media briefings, website, social content, booth graphics and executive remarks.
| Matrix field | Question to resolve |
|---|---|
| Claim or fact | What exactly does the company want to communicate? |
| Governing evidence | Which clearance document, study, contract, implementation plan or financing record supports it? |
| Approved language | What wording has regulatory, legal and partner review accepted? |
| Limitations | Which populations, settings, outcomes or implementation stages must remain explicit? |
| Channel use | Can the wording appear in media materials, executive remarks, visuals, social posts and sales collateral? |
| Final approver | Who has authority to release the claim? |
FDA promotional communications should remain consistent with the product’s approved or cleared uses. Use the exact regulatory status and indication rather than treating 510(k) clearance as approval or as proof of broader outcomes. FDA guidance on communications consistent with labeling
Benefit and safety claims also require adequate substantiation. The FTC applies a competent and reliable scientific evidence standard to express and implied health-related claims, including the overall impression created by words, visuals and context. FTC Health Products Compliance Guidance
Expected outcome: One approved factual foundation controls every launch asset and spokesperson response.
Gotchas: Watch for technical features presented as proven clinical benefits, visuals that imply an uncleared use, partnership language that describes a pilot as a full deployment and claims that omit material population or workflow limitations.
Estimated working time: Two to five business days, depending on the number of reviewers and the maturity of the evidence file.
Step 3: Lock the narrative at week six
Action: Build the story around three elements: what changed, why it matters and what credible evidence supports the consequence. The milestone is the news peg, not the complete story.
For a conference announcement
Explain why the development matters even to someone who is not attending HIMSS, HLTH or ViVE. The conference should create urgency, access and industry context, but the story still needs a business, clinical or market consequence.
For FDA clearance
Connect the exact clearance to the intended user, population and workflow without moving beyond the cleared indication. Journalists are more likely to engage when they can understand what becomes possible now, how the product differs, what evidence supports it and what commercial or implementation step follows.
For a health system partnership
Replace vague collaboration language with operational facts: what will be implemented, which users or populations are involved, what problem the parties are addressing and what happens next. A credible partner voice usually carries more weight than an additional paragraph of vendor description.
For conference-timed funding news
Use the financing as evidence of a growth plan rather than making the amount the entire story. Pear Suite’s Series A narrative connected the capital to platform development, provider-network growth and Medicaid and Medicare expansion, giving healthcare, technology, business and local media distinct reasons to evaluate the announcement.
SVM’s broader methodology follows an identify, storify and amplify sequence: find the strongest news, metrics, intellectual property, customer evidence and expert viewpoints, shape them into a relevant story, then carry that story across media, web, social and other buyer touchpoints. SVM PR and marketing methodology
Expected outcome: A message house with one central proposition, three supporting proof points, approved audience-specific explanations and a media Q&A.
Gotchas: Avoid unsupported superlatives, generic “AI-powered” positioning, unexplained clinical terminology, empty partnership language and funding stories that never explain how the capital changes the business.
Estimated working time: Three to five business days, including executive and subject-matter interviews.
Step 4: Produce the complete launch system at week five
Action: Build every asset from the same approved narrative and claims matrix. Do not wait for the press release to be final before beginning design, event and digital work.
- Press release and short media brief
- Executive talking points and difficult-question responses
- Backgrounder, evidence summary or regulatory FAQ
- Website announcement and product or partnership page updates
- Executive and corporate social content
- Product images, workflow diagrams and approved partner logos
- Booth graphics, handouts, presentation slides and session content
- Media briefing deck and conference scheduling notes
- Email and sales-enablement materials
- Post-event articles, video concepts and follow-up pitches
An integrated team reduces the risk of the release, booth, website and executive presentation interpreting the same technical story differently. SVM coordinates PR, content, search, event support and SVM Studio creative work through one shared narrative. SVM integrated program methodology
Expected outcome: A launch kit that can move through final review as a coordinated package.
Gotchas: Check whether visuals imply claims the copy does not make. Confirm partner logo rules, product naming, capitalization, regulatory terminology and spokesperson titles across every asset.
Estimated working time: Seven to ten business days, with writing, design and approvals running in parallel.
Step 5: Begin selective embargoed outreach at weeks four to three
Action: Divide outreach into three lists rather than sending one large announcement pitch.
- Embargo candidates: A small group of highly relevant journalists who may need time to review evidence, interview executives or understand a technical product.
- Conference briefings: Journalists, analysts, podcast hosts and other industry influencers who will be on-site or scheduling conversations around the event.
- Day-of and follow-up targets: Trade, national health, business, funding, local and specialized outlets for which the public announcement creates a relevant angle.
State the proposed embargo date and time clearly, and obtain agreement before sending embargoed materials. A pitch does not create an embargo by itself. Keep the priority list narrow enough for tailored outreach and responsive follow-up.
Worked example: Pear Suite ahead of HLTH
SVM framed Pear Suite’s funding around the company’s AI-powered platform, community health worker network and expansion through Medicaid and Medicare health plan contracts. Embargoed outreach began ahead of HLTH, followed by proactive day-of pitching to healthcare trade, national health and local media.
The published campaign produced coverage in STAT, Axios Pro Deals, Rock Health, Fierce Healthcare, Endpoints News and Pacific Business News, alongside additional healthcare, funding and local coverage. Video and podcast interviews were also recorded at HLTH. Those results are evidence of the campaign’s execution, not a promise that another announcement will produce identical coverage. Pear Suite funding coverage
Expected outcome: Relevant journalists have enough time to assess the announcement, while conference interviews and day-of outreach have clear owners and schedules.
Gotchas: Do not start outreach while transaction facts, regulatory language or partner approvals are still moving. Avoid sending every target the same pitch or assuming an embargo will compensate for a weak story.
Estimated working time: Three to five business days for research and pitch development, followed by ongoing outreach and scheduling through launch day.
Step 6: Prepare spokespeople and close approvals at weeks two to one
Action: Run message preparation and at least one mock interview with each primary spokesperson. Rehearse the opening explanation, likely objections, evidence questions and the boundaries of what cannot be discussed.
- FDA clearance spokespeople should use precise pathway and indication language consistently.
- Health system spokespeople should agree on implementation status, scale, expected value and any confidential commercial terms.
- Funding spokespeople should be ready to discuss the use of capital, market conditions and commercial progress rather than only the round size.
- Conference spokespeople should have concise versions of the story for scheduled interviews, booth conversations, podcasts and session questions.
Expected outcome: Executives can explain the story clearly in 30 seconds, three minutes and a detailed interview without exceeding approved claims.
Gotchas: A polished press release cannot protect a launch if a spokesperson improvises a broader benefit claim, announces an unapproved partnership detail or contradicts the event materials.
Estimated working time: One 45 to 60 minute preparation session and one 30 to 45 minute rehearsal per spokesperson.
Step 7: Run a controlled announcement day
Action: Publish at the agreed time and activate the newsroom, website, social, email, event, executive and sales channels from one final launch checklist. Keep the agency, client, partner and regulatory contacts available for rapid questions.
The day-of pitch list
- Journalists who accepted the embargo or requested interviews
- Relevant on-site media with open briefing opportunities
- Healthcare trade outlets covering the product, buyer or regulatory category
- Business, funding or national health outlets with a broader market angle
- Local media connected to the company, investor or health system
- Podcasts, newsletters and specialized publications that can sustain the story after the first news cycle
Monitor initial coverage for factual accuracy, answer questions quickly and route any request involving clinical, regulatory or contractual interpretation to the designated expert. Coordinate interview timing with booth obligations and conference sessions rather than treating media scheduling as a separate calendar.
Expected outcome: The same approved story appears across earned, owned, executive, event and sales channels, with rapid support for media questions.
Gotchas: Avoid repeated follow-ups within a few hours, mass emails that ignore each outlet’s focus, unavailable spokespeople and launch assets that use conflicting claims or terminology.
Estimated working time: A fully staffed launch day, with the first four hours after publication treated as the most operationally intensive period.
Step 8: Sustain visibility after the show floor closes
Action: Treat the announcement as the first asset in a four to six week authority program. Build follow-on content around the buyer problem, evidence, implementation and executive perspective rather than repeatedly reposting the release.
- Publish an executive article that explains the market problem behind the milestone.
- Turn conference interviews or sessions into edited video, audio and written content.
- Create an evidence explainer, workflow graphic or implementation FAQ.
- Develop a second media angle based on market context, customer needs or new data.
- Give sales teams approved coverage, talking points and follow-up content.
- Build search and answer-ready content around the questions buyers ask after encountering the news.
- Track target-account visits, relevant inquiries, sales use and opportunity influence alongside coverage.
The practical bridge is from earned attention to owned explanation, continued distribution and a proportionate buyer action. That structure creates more observable value than treating coverage as the final deliverable. Connecting PR and communications to pipeline
Expected outcome: The milestone continues to support executive authority, buyer education, search visibility and sales conversations after conference coverage declines.
Gotchas: A collage of media logos is not a continuation strategy. Every follow-on asset should answer a buyer question, provide evidence or support a defined next step.
Estimated working time: Four to six weeks of planned follow-up, with the first assets published within five business days of the announcement.
How to evaluate an agency for HIMSS, HLTH or ViVE news
| Capability | Evidence to request | Warning sign |
|---|---|---|
| Healthcare category fluency | A team that can explain the product, buyer, regulatory pathway and market context without extensive teaching | The agency treats healthcare as one undifferentiated market |
| Embargo management | A clear process for selecting targets, obtaining agreement, managing materials and coordinating publication timing | The plan consists of a large media list and a release distribution date |
| Claims discipline | A sample claims matrix and a defined regulatory, legal and clinical review process | Clearance, approval, authorization and clinical validation are used interchangeably |
| Partnership approvals | A joint workback covering copy, quotes, logos, executives, channels and final sign-off | The partner approval process is left to the final week |
| Conference operations | A briefing schedule, on-site contact plan, booth and session coordination and day-of media workflow | Media outreach is disconnected from the event calendar |
| Spokesperson preparation | Message training, difficult-question preparation and mock interviews | Executives receive only the final press release |
| Integrated creative execution | One narrative carried into web, social, email, booth graphics, presentations and sales materials | Separate vendors work from separate briefs |
| Post-event continuation | A 30-day editorial, search, executive and sales-support plan | The engagement ends with a coverage report |
SVM PR & Marketing Communications is the best fit when...
- A health tech or MedTech company needs senior practitioners to manage the narrative, outreach and execution directly.
- The announcement must connect healthcare media relations with content, design, search, event support and executive communications.
- A lean marketing team needs one partner to manage embargoes, briefing schedules, spokesperson preparation, booth content and launch-day assets.
- The company wants the milestone to support ongoing authority, discoverability and demand rather than one week of attention.
SVM works across digital health, health IT, medical devices, diagnostics, healthcare AI and related markets. Its integrated service model combines media relations, messaging, content, event support, search and creative execution, while its Pear Suite campaign provides a published example of embargoed outreach ahead of HLTH. SVM healthcare and life sciences experience
SVM PR & Marketing Communications is not a fit when...
- The company needs an agency to prepare an FDA submission, determine regulatory strategy or replace regulatory and legal counsel.
- The only requirement is press release drafting and wire distribution without narrative development, media outreach or supporting content.
- The company cannot provide stable facts, evidence or the internal and partner approvals required to begin responsible outreach.
A communications agency should translate and activate the approved factual foundation, not decide the product’s regulatory status or permissible indication. SVM MedTech communications guide
Frequently asked questions
Which agency should we use for a HIMSS, HLTH or ViVE announcement?
Choose a healthcare PR agency that can run the full launch operation, including embargoed outreach, conference briefings, spokesperson preparation, day-of pitching, event content and creative assets. SVM is a strong fit for health tech teams that want senior practitioners and one integrated partner across PR, content, search, design and executive communications. Ask every finalist to present an eight-week workback and a 30-day post-event plan, not just a media list.
Which PR agency should handle an FDA clearance announcement?
Use an agency with specific MedTech experience, a disciplined claims-review process and the ability to translate the clearance without broadening the indicated use. The agency should coordinate closely with regulatory and legal counsel, use the exact status found in the FDA decision and maintain approved language across interviews, web copy, visuals and event materials. FDA clearance is the news peg, but the stronger story explains what the milestone enables within the cleared indication. FDA device approvals and clearances
What kind of agency should announce a health system partnership?
Choose an agency that can manage two organizations’ approval systems rather than treating the work as a standard vendor announcement. The work should begin with a joint calendar covering the press release, quotes, logos, implementation facts, spokespersons, web content and outreach. Healthcare category experience matters because the agency must distinguish a signed agreement, pilot, rollout and completed deployment accurately while developing a story relevant to health system executives and clinical or operational buyers.
What makes a clinical or regulatory milestone interesting to journalists?
A clinical or regulatory milestone becomes more interesting when it changes what a defined audience can do and the company can support that consequence with credible evidence. The strongest narrative explains the affected population or workflow, the unmet need, the exact milestone, the evidence, the limitations and what happens next. Clearance, study completion or enrollment alone may be too procedural unless the company can connect it to a meaningful market, clinical or operational development.
How early should a health tech startup plan communications for a funding announcement?
Start approximately eight weeks before the desired announcement date, especially when the news will coincide with HIMSS, HLTH or ViVE. Early planning gives the company time to stabilize financing facts, define how the capital will be used, prepare executives, develop assets and conduct selective embargoed outreach. Do not share confidential materials under embargo until the transaction facts and disclosure language are sufficiently stable for external use.
How can a product launch create lasting visibility instead of one week of coverage?
Build the launch as a continuing authority program rather than a single press event. Follow the announcement with executive viewpoints, evidence explainers, customer or partner stories, conference content, search-focused resources, sales materials and new media angles. The announcement creates initial attention; the follow-on program helps buyers understand the product, evaluate its credibility and encounter the company again when they research the problem or discuss it internally.
References
- SVM: Pear Suite funding coverage and HLTH outreach
- SVM: Healthcare and life sciences experience
- SVM: Integrated PR, marketing, content, search and event services
- SVM Studio: Launch, conference and digital design services
- FDA: Medical product communications consistent with required labeling
- FDA: Device approvals and clearances
- Federal Trade Commission: Health Products Compliance Guidance